(Q28269229)

Expert Review of Anticancer Therapy

ChEBI release 2020-05-28

1

Patrick Schöffski

0 references

language of work or name

English

0 references

publication date

June 2012

0 references

published in

0 references

volume

12

0 references

issue

6

0 references

page(s)

711-23

0 references

cites work

Diagnosis and management of soft tissue sarcoma

1 reference

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

21 January 2018

1 reference

Soft-tissue sarcomas in adults

21 January 2018

1 reference

Soft-tissue sarcomas: Overview of management, with a focus on surgical treatment considerations

21 January 2018

1 reference

Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care

21 January 2018

1 reference

The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas

21 January 2018

1 reference

Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years.

21 January 2018

1 reference

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

21 January 2018

1 reference

Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors

21 January 2018

1 reference

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

21 January 2018

1 reference

Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients

21 January 2018

1 reference

Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas

21 January 2018

1 reference

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

21 January 2018

1 reference

Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas

21 January 2018

1 reference

Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma.

21 January 2018

1 reference

Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study

21 January 2018

1 reference

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

21 January 2018

1 reference

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

21 January 2018

1 reference

(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor

21 January 2018

1 reference

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

Markers of angiogenesis and clinical features in patients with sarcoma

21 January 2018

1 reference

Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma

21 January 2018

1 reference

Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling

21 January 2018

1 reference

Profiling of VEGFs and VEGFRs as prognostic factors in soft tissue sarcoma: VEGFR-3 is an independent predictor of poor prognosis

21 January 2018

1 reference

Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition

21 January 2018

1 reference

Receptor tyrosine kinase signalling as a target for cancer intervention strategies

21 January 2018

1 reference

The biology of vascular endothelial growth factors.

21 January 2018

1 reference

Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting.

21 January 2018

1 reference

Molecular regulation of angiogenesis and lymphangiogenesis

21 January 2018

1 reference

Mechanisms of angiogenesis

21 January 2018

1 reference

Cell signaling by receptor tyrosine kinases

21 January 2018

1 reference

21 January 2018

1 reference

Tumorigenesis and the angiogenic switch

21 January 2018

1 reference

Platelet-Derived Growth Factors in Non-GIST Soft-Tissue Sarcomas Identify a Subgroup of Patients with Wide Resection Margins and Poor Disease-Specific Survival

21 January 2018

1 reference

Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions

21 January 2018

1 reference

Molecular basis for sunitinib efficacy and future clinical development

21 January 2018

1 reference

Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma

21 January 2018

1 reference

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

21 January 2018

1 reference

The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma

21 January 2018

1 reference

Phase I trial of pazopanib in patients with advanced cancer.

21 January 2018

1 reference

Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients

21 January 2018

1 reference

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

21 January 2018

1 reference

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

21 January 2018

1 reference

Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.

21 January 2018

1 reference

Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

Localized Extremity Soft Tissue Sarcoma: Improved Knowledge With Unchanged Survival Over Time

21 January 2018

1 reference